Remarkably, PD-L1 expression, tumor mutation burden, and infiltrating lymphocytes (TILs) have long been proposed as reliable indicators for immune checkpoint inhibitors (ICIs) treatment [12]. This evidence concerns the gene CD274 and neoplasm.